DUSA Pharmaceuticals, Inc. (NASDAQ:DUSA)

CAPS Rating: 3 out of 5

A dermatology company, which is engaged in the development and marketing Levulan photodynamic therapy and other products for common skin conditions.

Recs

0
Player Avatar cbibuld (41.66) Submitted: 1/12/2012 4:48:48 PM : Outperform Start Price: $4.60 DUSA Score: +15.57

Company earnings turned positive 2nd hald of 2011 and look to be continuing down that path. Last year grew +20% revenues. Thompson puts street est of .13/.12 for 4th qtr. Y/y would equal .30/.11 p/s.

Featured Broker Partners


Advertisement